Clinical trials: Leukoderma, open to volunteers
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
- Conditions
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
- Trial name
- NCT06805825
- Testing
- NN3201
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Novelty Nobility, Inc.
NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable…
- Trial name
- MTII-VIT (NCT07437560)
- Testing
- Melanotan II (MT-II), Narrowband UV-B (NB-UVB) phototherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hudson Biotech
Vitiligo, Non-Segmental Vitiligo (NSV)
Study of D-2570 in Subjects With Non-Segmental Vitiligo
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
- Trial name
- D2570-206 (NCT07625891)
- Testing
- D-2570 Dose 1, D-2570 Dose 2, D-2570 Dose 3
- Where
- China
- Volunteers
- 160 people
- Sponsor
- InventisBio Co., Ltd
Vitiligo
A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo
This is a randomized, double-blind, placebo-controlled Phase Ib/II clinical trial of multiple subcutaneous injections of GR2301 in combination with phototherapy to evaluate the tolerability, safety, pharmacokinetics, and…
- Trial name
- GREVIT (NCT07647237)
- Testing
- GR2301 injection
- Volunteers
- 116 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Non-segmental Vitiligo
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into…
- Trial name
- VITESS (NCT07431177)
- Testing
- GIA632
- Where
- 83 sites in United States, Argentina and 10 more
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Solar Lentigo
CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS
To assess the efficacy of the Epilady investigational device, used with and without a topical depigmenting formula, in reducing the appearance of lentigo spots on the hands and forearms of healthy female participants over an…
- Trial name
- EPILADY (NCT07239726)
- Testing
- LASER, LASER AND ACTIVE FORMULA
- Where
- Mauritius
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Vitiligo
A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo
The goal of this clinical trial is to learn if drug CGB-600 works to treat vitiligo on the face and neck in participants between 18-60 years of age. It will also learn about the safety of CGB-600.
- Trial name
- NCT07357870
- Testing
- Drug: CGB-600 gel, experimental drug
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- CAGE Bio Inc.
Vitiligo
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo
This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.
- Trial name
- NCT07682506
- Testing
- MH004 1.0% Ointment
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Vitiligo
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.
- Trial name
- NCT06625177
- Testing
- TEV-53408
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Vitiligo, Non-Segmental Vitiligo (NSV)
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo.
- Trial name
- NCT07533019
- Testing
- LY4005130
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company